Bevacizumab: a new way of doing business. Part 2

doi:10.1038/s41433-018-0281-2

Editorial

. 2019 Apr;33(4):519-520.

doi: 10.1038/s41433-018-0281-2. Epub 2018 Nov 27.

Bevacizumab: a new way of doing business. Part 2

Andrew J Lotery¹, Michael A Burdon²

Affiliations

¹ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, South Lab and Path Block, Mailpoint 806, Level D, University Hospital Southampton, Southampton SO16 6YD, Southampton, UK. a.j.lotery@soton.ac.uk.
² Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, NHS Foundation Trust, Mindelsohn Way Edgbaston, Birmingham, B15 2TH, UK.

PMID: 30482906
PMCID: PMC6461904
DOI: 10.1038/s41433-018-0281-2

Editorial

Bevacizumab: a new way of doing business. Part 2

Andrew J Lotery et al. Eye (Lond). 2019 Apr.

. 2019 Apr;33(4):519-520.

doi: 10.1038/s41433-018-0281-2. Epub 2018 Nov 27.

Authors

Andrew J Lotery¹, Michael A Burdon²

Affiliations

¹ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, South Lab and Path Block, Mailpoint 806, Level D, University Hospital Southampton, Southampton SO16 6YD, Southampton, UK. a.j.lotery@soton.ac.uk.
² Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, NHS Foundation Trust, Mindelsohn Way Edgbaston, Birmingham, B15 2TH, UK.

PMID: 30482906
PMCID: PMC6461904
DOI: 10.1038/s41433-018-0281-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

1. Canning C, Lotery A. Bevacizumab: a new way of doing business? Eye. 2007;21(6):891–891. doi: 10.1038/sj.eye.6702777. - DOI - PubMed
1. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–67. doi: 10.1016/S0140-6736(13)61501-9. - DOI - PubMed
1. Lotery A, MacEwen C. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? BMJ. 2014;349:g6887. doi: 10.1136/bmj.g6887. - DOI - PubMed
1. Shalaby AK, Lewis K, Bush K, Meredith PR, Di Simplicio S, Lockwood AJ. Licence to save: a UK survey of anti-VEGF use for the eye in 2015. Eye (Lond) 2016;30(11):1404–6. doi: 10.1038/eye.2016.154. - DOI - PMC - PubMed
1. Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. Eye (Lond) 2017;31(5):771–5. doi: 10.1038/eye.2017.1. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Canning C, Lotery A. Bevacizumab: a new way of doing business? Eye. 2007;21(6):891–891. doi: 10.1038/sj.eye.6702777. - DOI - PubMed

[2] Canning C, Lotery A. Bevacizumab: a new way of doing business? Eye. 2007;21(6):891–891. doi: 10.1038/sj.eye.6702777. - DOI - PubMed

[3] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–67. doi: 10.1016/S0140-6736(13)61501-9. - DOI - PubMed

[4] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–67. doi: 10.1016/S0140-6736(13)61501-9. - DOI - PubMed

[5] Lotery A, MacEwen C. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? BMJ. 2014;349:g6887. doi: 10.1136/bmj.g6887. - DOI - PubMed

[6] Lotery A, MacEwen C. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? BMJ. 2014;349:g6887. doi: 10.1136/bmj.g6887. - DOI - PubMed

[7] Shalaby AK, Lewis K, Bush K, Meredith PR, Di Simplicio S, Lockwood AJ. Licence to save: a UK survey of anti-VEGF use for the eye in 2015. Eye (Lond) 2016;30(11):1404–6. doi: 10.1038/eye.2016.154. - DOI - PMC - PubMed

[8] Shalaby AK, Lewis K, Bush K, Meredith PR, Di Simplicio S, Lockwood AJ. Licence to save: a UK survey of anti-VEGF use for the eye in 2015. Eye (Lond) 2016;30(11):1404–6. doi: 10.1038/eye.2016.154. - DOI - PMC - PubMed

[9] Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. Eye (Lond) 2017;31(5):771–5. doi: 10.1038/eye.2017.1. - DOI - PMC - PubMed

[10] Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. Eye (Lond) 2017;31(5):771–5. doi: 10.1038/eye.2017.1. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Bevacizumab: a new way of doing business. Part 2

Affiliations

Bevacizumab: a new way of doing business. Part 2

Authors

Affiliations

Conflict of interest statement

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical